Inhibrx reported top‑line results from a registrational Phase II, showing ozekibart (INBRX‑109) achieved a statistically significant improvement in median progression‑free survival for advanced or metastatic unresectable chondrosarcoma. The placebo‑controlled study met its primary endpoint and produced clinically meaningful benefits in a rare tumor type with limited options. Inhibrx said the data support plans to file a biologics license application (BLA) in the second half of 2026, and the results drove a sharp intraday jump in the company’s stock. The company highlighted the unmet need in this slow‑growing bone cancer and framed ozekibart as a potential first approved therapy.